Regulatory innovation and drug development for early-stage Alzheimer's disease

N Engl J Med. 2013 Mar 28;368(13):1169-71. doi: 10.1056/NEJMp1302513. Epub 2013 Mar 13.

Authors

Nicholas Kozauer¹, Russell Katz

Affiliation

¹ Division of Neurology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

PMID: 23484795
DOI: 10.1056/NEJMp1302513

No abstract available

MeSH terms

Alzheimer Disease / drug therapy*
Amyloid beta-Peptides / drug effects
Amyloid beta-Peptides / metabolism
Biomarkers / metabolism
Drug Discovery / legislation & jurisprudence*
Government Regulation
Humans
United States
United States Food and Drug Administration

Substances

Amyloid beta-Peptides
Biomarkers